Akt Inhibitor Arq 092 and Sorafenib Additively Inhibit Progression of Hepatocellular Carcinoma and Improve Immune System in Cirrhotic Rat Model
| dc.contributor.author | Jilkova, Z. M. | |
| dc.contributor.author | Zeybek Kuyucu, Ayça | |
| dc.contributor.author | Kurma, K. | |
| dc.contributor.author | Pour, S. T. A. | |
| dc.contributor.author | Roth, G. S. | |
| dc.contributor.author | Abbadessa, G. | |
| dc.contributor.author | Decaens, T. | |
| dc.coverage.doi | 10.1016/S0168-8278(17)31736-1 | |
| dc.date.accessioned | 2020-07-25T22:12:32Z | |
| dc.date.available | 2020-07-25T22:12:32Z | |
| dc.date.issued | 2017 | |
| dc.description | International Liver Congress / 52nd Annual Meeting of the European-Association-for-the-Study-of-the-Liver -- APR 19-23, 2017 -- Amsterdam, NETHERLANDS | en_US |
| dc.description.abstract | Background and Aims: Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages with limited number of therapeutic options. Longer exposure to classical treatment of advanced HCC, sorafenib, often over-activates AKT pathway, leading to HCC resistance. Moreover, AKT pathway itself is activated in almost half of HCC cases. Therefore, we investigated the efficacy of combination of Sorafenib with allosteric Akt inhibitor ARQ 092 in a DEN-induced cirrhotic rat model with HCC. | en_US |
| dc.identifier.doi | 10.1016/S0168-8278(17)31736-1 | en_US |
| dc.identifier.issn | 0168-8278 | |
| dc.identifier.issn | 1600-0641 | |
| dc.identifier.uri | https://doi.org/10.1016/S0168-8278(17)31736-1 | |
| dc.identifier.uri | https://hdl.handle.net/11147/9455 | |
| dc.language.iso | en | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.ispartof | Journal of Hepatology | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Akt Inhibitor Arq 092 and Sorafenib Additively Inhibit Progression of Hepatocellular Carcinoma and Improve Immune System in Cirrhotic Rat Model | en_US |
| dc.type | Conference Object | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Zeybek Kuyucu, Ayça | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::conference output | |
| gdc.collaboration.industrial | true | |
| gdc.description.department | İzmir Institute of Technology. Bioengineering | en_US |
| gdc.description.endpage | S641 | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | S641 | en_US |
| gdc.description.volume | 66 | en_US |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W2612191578 | |
| gdc.identifier.wos | WOS:000401056601578 | |
| gdc.index.type | WoS | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 0.0 | |
| gdc.oaire.influence | 2.635068E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.popularity | 1.12126E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 0303 health sciences | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 0.0 | |
| gdc.openalex.normalizedpercentile | 0.06 | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.mendeley | 1 | |
| gdc.wos.citedcount | 0 | |
| local.message.claim | 2022-06-09T09:56:55.140+0300 | * |
| local.message.claim | |rp03017 | * |
| local.message.claim | |submit_approve | * |
| local.message.claim | |dc_contributor_author | * |
| local.message.claim | |None | * |
| relation.isAuthorOfPublication.latestForDiscovery | 2a56a7fd-7c18-42fd-a7e2-9d84206520de | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4015-8abe-a4dfe192da5e |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 1-s2.0-S0168827817317361-main.pdf
- Size:
- 61.74 KB
- Format:
- Adobe Portable Document Format